Université Paris-Saclay, UVSQ, ERPHAN, Versailles, France.
Centre de Recherche de l'Institut, Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Respir Care. 2020 Sep;65(9):1346-1354. doi: 10.4187/respcare.07306. Epub 2020 Apr 14.
High-flow nasal cannula (HFNC) is increasingly used in the management of acute and chronic respiratory failure. Little is known about the optimal settings for HFNC. This study was designed to assess the dose effect of HFNC on respiratory effort indexes and respiratory patterns in spontaneously breathing adults.
A randomized controlled crossover study was conducted in 10 healthy subjects. Five experimental conditions were evaluated: baseline with no therapy; 5 L/min with conventional nasal prongs; and HFNC at 20, 40, and 60 L/min. The primary outcomes were the indexes of respiratory effort (ie, esophageal pressure swing [ΔP], esophageal pressure-time product, and work of breathing). Secondary outcomes included breathing pattern parameters and blood gases. Dead-space ventilation and washout were calculated based on minute ventilation, breathing frequency, and Radford equations.
ΔP increased from median (interquartile range [IQR] 3.2 (2.2-3.6) cm HO at baseline to median (IQR) 5.7 (4.6-6.8) cm HO at 60 L/min ( < .001). Neither esophageal pressure-time product nor work of breathing were modified during the tested conditions. The minute volume was significantly reduced at 40 and 60 L/min compared with baseline = .04), mostly driven by an important and dose-dependent reduction in breathing frequency, from median (IQR) 16 (15-18) breaths/min at baseline, to median (IQR) 8 (7-10) breaths/min at 60 L/min ( < .001). Capillary [Formula: see text] was stable in all the tested conditions. The calculated dead-space ventilation was reduced by half with HFNC.
HFNC did not significantly modify work of breathing in healthy subjects. However, a significant reduction in the minute volume was achieved, capillary [Formula: see text] remaining constant, which suggests a reduction in dead-space ventilation with flows > 20 L/min. (ClinicalTrials.gov registration NCT02495675).
高流量鼻导管(HFNC)在急性和慢性呼吸衰竭的治疗中应用越来越广泛。但对于 HFNC 的最佳设置知之甚少。本研究旨在评估 HFNC 对自主呼吸成人呼吸努力指标和呼吸模式的剂量效应。
在 10 名健康受试者中进行了一项随机对照交叉研究。评估了 5 种实验条件:无治疗的基础状态;常规鼻塞 5 L/min;HFNC 20、40 和 60 L/min。主要结局指标为呼吸努力指数(即食管压力摆动[ΔP]、食管压力时间乘积和呼吸功)。次要结局指标包括呼吸模式参数和血气。死腔通气量和冲洗量根据分钟通气量、呼吸频率和 Radford 方程计算。
ΔP 从基础状态的中位数(四分位距[IQR] 3.2(2.2-3.6)cm H2O)增加到 60 L/min 时的中位数(IQR)5.7(4.6-6.8)cm H2O(<.001)。在测试条件下,食管压力时间乘积和呼吸功均未改变。与基础状态相比,40 和 60 L/min 时分钟通气量显著降低(<.001),主要是由于呼吸频率显著且呈剂量依赖性降低,从基础状态的中位数(IQR)16(15-18)次/分降至 60 L/min 时的中位数(IQR)8(7-10)次/分(<.001)。所有测试条件下的毛细血管[Formula: see text]均稳定。HFNC 可将死腔通气量减少一半。
HFNC 并未显著改变健康受试者的呼吸功。然而,分钟通气量显著降低,而毛细血管[Formula: see text]保持不变,提示流量>20 L/min 时死腔通气量减少。(ClinicalTrials.gov 注册号 NCT02495675)。